EGM
ATRA icon

Engineers Gate Manager’s Atara Biotherapeutics ATRA Stock Holding History

Engineers Gate Manager’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,192
Closed -$20.7K – 1915
2024
Q1 		$20.7K Sell
1,192
-12
-1% -$213 ﹤0.01% 1840
2023
Q4 		$15.4K Buy
1,204
+639
+113% +$14.9K ﹤0.01% 1918
2023
Q3 		$20.9K Buy
+565
New +$25.1K ﹤0.01% 1705
2022
Q2 		– Sell
-656
Closed -$152K – 1890
2022
Q1 		$152K Sell
656
-1,171
-64% -$373K 0.01% 1659
2021
Q4 		$720K Buy
+1,827
New +$769K 0.03% 808
2021
Q3 		– Sell
-853
Closed -$332K – 1631
2021
Q2 		$332K Sell
853
-533
-38% -$190K 0.02% 1065
2021
Q1 		$498K Buy
1,386
+705
+104% +$312K 0.02% 992
2020
Q4 		$334K Sell
681
-200
-23% -$92.3K 0.01% 1226
2020
Q3 		$286K Buy
+881
New +$300K 0.01% 1276

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Engineers Gate Manager's ATRA Position: Q2 2024 in Review

Engineers Gate Manager sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 1,192 shares — an estimated $20.7K sold.

Engineers Gate Manager first reported a position in ATRA in Q3 2020 and held it in 9 quarters. The position peaked at $720K in Q4 2021. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Engineers Gate Manager reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Engineers Gate Manager sold 1,192 Atara Biotherapeutics shares in Q2 2024, an estimated $20.7K.
  • Engineers Gate Manager first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 9 quarters.
  • Engineers Gate Manager's Atara Biotherapeutics position peaked at $720K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Engineers Gate Manager's 13F filing for Q2 2024, filed 14 Aug 2024.